Breakdown | ||||
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
306.00K | 268.00K | 82.00K | 25.00K | 36.00K | Gross Profit |
96.00K | 75.00K | 45.00K | 14.00K | 18.00K | EBIT |
-39.82M | -45.65M | -35.40M | -17.97M | -16.56M | EBITDA |
-35.29M | -42.91M | -33.60M | -17.11M | -13.60M | Net Income Common Stockholders |
-36.24M | -44.25M | -36.23M | -21.61M | -20.44M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
49.08M | 82.70M | 105.11M | 13.53M | 21.39M | Total Assets |
95.44M | 116.33M | 147.03M | 14.80M | 23.26M | Total Debt |
1.86M | 2.31M | 128.00K | 8.67M | 9.31M | Net Debt |
-2.02M | -27.57M | -58.80M | -4.86M | -12.07M | Total Liabilities |
25.28M | 17.39M | 8.46M | 140.37M | 129.88M | Stockholders Equity |
70.16M | 98.94M | 138.56M | -125.57M | -106.62M |
Cash Flow | Free Cash Flow | |||
-27.32M | -35.40M | -32.94M | -17.02M | -19.43M | Operating Cash Flow |
-27.19M | -34.61M | -31.64M | -16.87M | -19.32M | Investing Cash Flow |
438.00K | 5.55M | -82.56M | -149.00K | -6.00K | Financing Cash Flow |
752.00K | 5.00K | 159.59M | 9.16M | 33.05M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | $76.25M | ― | -93.78% | ― | 5.89% | 38.12% | |
52 Neutral | $5.28B | 3.75 | -42.72% | 2.86% | 17.70% | 2.03% | |
51 Neutral | $85.63M | ― | -345.31% | ― | 28.29% | 23.11% | |
46 Neutral | $149.43M | ― | -84.46% | ― | -40.09% | -18.67% | |
42 Neutral | $77.03M | ― | -337.30% | ― | 45.30% | 45.67% | |
36 Underperform | $110.37M | ― | -55.78% | ― | -74.84% | 14.63% | |
29 Underperform | $48.37M | ― | 138.92% | ― | 59.10% | 37.59% |
On February 10, 2025, Sera Prognostics announced a public offering of its Class A common stock and pre-funded warrants, expecting to raise approximately $50 million. The proceeds are intended to enhance U.S. commercial infrastructure, prepare for EU expansion, and support studies for the PreTRM test, with a potential FDA submission for broader approval.